Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II/III study for its Category 1 product, jacktinib cream, in adolescent and adult patients suffering from non-segmental vitiligo.
Jacktinib, a Janus kinase (JAK) inhibitor, exhibits a significant inhibitory effect on Janus kinases, including JAK1, JAK2, JAK3, and TYK2, with the most potent effects observed against JAK2 and TYK2. The drug’s market filing for the treatment of medium- to high-risk myelofibrosis (MF) was accepted for review by the NMPA in October 2022, indicating its potential in addressing various conditions related to the JAK pathway.- Flcube.com
